All News

Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/vwNFU501di
Dr. John Cush RheumNow ( View Tweet)
Early Rx doesnt prevent Difficult to Tx RA (D2TRA). Propective study of 722 early RA pts Rx w/ MTX found after 73 mos 29% were D2TRA. 21.5% Rx w/ b/tsDMARD after 19 mos, yet 70% were uncontrolled. 5 yr retention rates were 40%. D2T predicted by pain & swollen joints… https://t.co/veaspuCHIE https://t.co/zjlTWQn4GQ
Dr. John Cush RheumNow ( View Tweet)
biosimilars2.jpg

Biosimilar Slow Growth in USA

d Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Read Article
Korean database of 43,502 #AS pts found CV events based on Rx exposure. CV event rates were: No bDMARDS (18.66/10K PYs), TNFi (8.92), & IL-17i (12.87). TNFi significantly lowered rate of CVE (aHR 0.69), but IL-17i did not (0.96) https://t.co/LMzPodWI5v https://t.co/rQ0aq1ALgW

Links:

Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology. - Uveitis accounts for 10% of visual impairment globally - TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/CmGuA7W4Ag https://t.co/p5aEQlV7p6

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Dr. Quotes (11.8.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
Liver.hepatitis.jpg

Advances in the treatment of autoimmune hepatitis

d EurekAlert!

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure. 

Read Article
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
Swapping is Better than Cycling in Psoriatic Arthritis A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Happy Diwali (11.1.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
switch.jpg

Swapping is Better than Cycling in Psoriatic Arthritis

d Jack Cush, MD

A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.

Read Article
Pain Relief in RA: JAK Better than TNF Inhibitors? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today! https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o

Links:

Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX. Join the Revolution in Rheumatology Education! https://t.co/ygjZRMVkOZ

Links:

Dr. John Cush RheumNow ( View Tweet)

World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open! https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean Claims analysis of 413 radiographic axial spondyloarthritis (TNFi exposed=75 ). Recurrent CV events = 32 per 1,000 person-years; but lower if TNFi Rx'd = 19/1000PYs. TNFi exposure significantly lowered risk of recurrent CV events https://t.co/f69SHpXZCx https://t.co/ofpg0JbrR1

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.